HC Wainwright Cuts Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $13.00

Unicycive Therapeutics (NASDAQ:UNCY) had its price target reduced by research analysts at HC Wainwright from $15.00 to $13.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 188.25% from the company’s current price.

Several other brokerages also recently commented on UNCY. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research upgraded shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. B. Riley Financial reissued a “buy” rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Finally, Guggenheim reiterated a “buy” rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Unicycive Therapeutics Stock Down 2.8%

NASDAQ UNCY traded down $0.13 on Tuesday, reaching $4.51. The company had a trading volume of 1,290,779 shares, compared to its average volume of 920,126. The stock’s 50 day moving average is $5.17 and its 200-day moving average is $6.32. The stock has a market cap of $125.60 million, a price-to-earnings ratio of -2.60 and a beta of 1.79. Unicycive Therapeutics has a 52 week low of $3.93 and a 52 week high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.41. As a group, analysts forecast that Unicycive Therapeutics will post -1.17 EPS for the current year.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently modified their holdings of UNCY. Renaissance Technologies LLC bought a new position in Unicycive Therapeutics in the first quarter valued at $161,000. Bank of America Corp DE grew its stake in Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares in the last quarter. Seven Fleet Capital Management LP grew its stake in Unicycive Therapeutics by 85.6% in the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock valued at $521,000 after purchasing an additional 47,700 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Unicycive Therapeutics during the 2nd quarter worth approximately $248,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Unicycive Therapeutics during the 1st quarter worth approximately $940,000. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics News Summary

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Unicycive announced that it has resubmitted its New Drug Application for oxylanthanum carbonate (OLC), an investigational phosphate binder for dialysis patients with chronic kidney disease. The company expects the FDA to accept the application within 30 days and assign a new PDUFA decision date approximately six months after resubmission, restoring a potential regulatory path for its lead product. Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
• Neutral Sentiment: Multiple law firms reiterated that investors who purchased UNCY securities between December 29, 2025, and June 29, 2026, have until November 2, 2026, to seek appointment as lead plaintiff in a pending federal securities class action. These notices are largely duplicative and do not represent new judicial findings. Faruqi & Faruqi Unicycive Securities Class Action Notice
• Negative Sentiment: The lawsuit-related announcements allege that Unicycive resubmitted the OLC application without inspecting its third-party manufacturer’s facility for current good manufacturing practice compliance. The complaints also contend that the company had promoted an FDA decision and potential commercial launch despite manufacturing concerns linked to an earlier Complete Response Letter. If proven, the allegations could create legal costs, reputational damage, and additional uncertainty around OLC’s approval timeline. Bronstein Gewirtz Grossman Unicycive Class Action Notice

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company’s lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.